BiondVax Pharmaceuticals Ltd.

BiondVax did not report quarterly revenue or EPS on this call. Management said it held $17.4 million in cash at year-end in one comment, and $17.5 million in cash in another, and that it raised $9.8 million in December 2021. The company said it expects to burn approximately $1 million per month, or over $3 million per quarter, in 2022 toward first-in-human trials. On guidance, it expects to complete technology transfer and animal proof-of-concept work, then initiate first-in-human COVID-19 NanoAb trials in 2023, with a worst-case path to marketing authorization filing in 2026 if the pandemic subsides.

Amir Reichman framed BiondVax as transitioning from a single product story to a platform story, with COVID-19 NanoAb as the lead program and nine additional NanoAbs as follow-on opportunities. He emphasized risk reduction through already-validated targets, access to world-class academic partners, and in-house GMP manufacturing in Jerusalem. His tone was upbeat and promotional, repeatedly describing the company as undervalued and saying the strategy and assets could support significant future value creation.

No separate CFO spoke on the call. Amir Reichman provided the financial commentary, saying BiondVax agreed in principle to restructure €24 million of EIB debt by extending maturity to December 31, 2027, with a bullet repayment and royalties tied to future net sales. He also said the company had $17.4 million to $17.5 million in cash at year-end, had raised $9.8 million in December 2021, and expects a burn of about $1 million per month in 2022. He said that funding should be enough to carry the company to first-in-human studies, while also noting possible future capital raising through partnerships, sublicensing, non-dilutive funding, or the public market if needed.

Analysts focused on the advantages and risks of NanoAbs, the expected retail price of the COVID treatment, development catalysts, timing to market, competition, and funding needs. Management said NanoAbs may offer greater potency, stability, lower dosing, and possibly fewer side effects, while acknowledging biological risks such as immune responses and on-target effects. On pricing, Amir said the company expects to be substantially below the roughly $2,000-plus administration cost he cited for Vir/GSK, but did not give a specific price. He said the earliest filing for marketing approval could be 2026 in a lower-infection scenario, but faster if the pandemic worsens, and reiterated that cash should cover first-in-human work while additional funding options remain under review.